Nonalcoholic Fatty Liver Disease : The New Complication of Type 2 Diabetes Mellitus - 04/11/16

Doi : 10.1016/j.ecl.2016.06.005

Fernando Bril, MD ^a, Kenneth Cusi, MD ^a,^b,^⁎
^a Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, 1600 South West Archer Road - Room H2, Gainesville, FL 32610, USA
^b Division of Endocrinology, Diabetes, and Metabolism, Malcom Randall Veterans Affairs Medical Center, 1601 South West Archer Road, Gainesville, FL 32608, USA

^∗Corresponding author. Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Florida College of Medicine, 1600 Southwest Archer Road, Room H-2, Gainesville, FL 32610.Division of Endocrinology, Diabetes and MetabolismDepartment of MedicineUniversity of Florida College of Medicine1600 Southwest Archer RoadRoom H-2GainesvilleFL32610

Résumé

Nonalcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus (T2DM), with an estimated prevalence of 60% to 80%. The relationship of NAFLD and T2DM is complex, with each condition negatively affecting the other. Although NAFLD is associated with more metabolic and cardiovascular complications and worse hyperglycemia, T2DM accelerates the progression of liver disease in NAFLD. Despite the high prevalence and serious clinical implications, NAFLD is usually overlooked in clinical practice. This article focuses on understanding the relationship between NAFLD and T2DM, to provide better care for these complex patients.

Le texte complet de cet article est disponible en PDF.

Keywords : Obesity, Nonalcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), Thiazolidinediones, Pioglitazone, Diabetes, Insulin resistance

Plan

Metabolic and cardiovascular implications

Diagnosis

Treatment

Diet and Lifestyle Intervention

Insulin Sensitizers in Nonalcoholic Steatohepatitis: Role of Pioglitazone

Glucagonlike Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Sodium-Glucose Cotransporter 2 Inhibitors

Other Pharmacologic Treatments Tested in Patients Without Diabetes

Summary

Disclosure: K. Cusi has received research support from Janssen and Novartis, and served as a consultant for (in alphabetical order) Janssen, Lilly, Pfizer, and Tobira Therapeutics, Inc; F. Bril has nothing to disclose.